Skip to content

Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth

Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01969461
Enrollment
400
Registered
2013-10-25
Start date
2014-07-31
Completion date
2018-12-31
Last updated
2017-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Keywords

HIV positive, Adolescents, Adolescent Trials Network, Comparative Effectiveness Trial, Implementation, Adherence Intervention, Alcohol Intervention

Brief summary

Alcohol use among persons with HIV exacerbates health problems and accelerates HIV disease progression. Antiretroviral therapy (ART) is the single most important treatment for people living with HIV. However, ART adherence is suboptimal among adolescents and young adults living with HIV, the age group with the fastest growing rates of HIV infection, and great risk of engaging in risky behaviors such as alcohol use. The proposed study will compare the effectiveness of home-based versus clinic-based Healthy Choices, a brief, 4- session intervention using Motivational Enhancement Therapy (MET) to address alcohol use, medication adherence, and health outcomes in youth living with HIV (YLH) using a repeated measures design. Unlike previous trials, Healthy Choices will be tested in a real world clinical setting and be delivered by community health workers (CHW: already members of the HIV care team). The study population will consist of YLH, ages 16-24, who are current patients at 5 ATN sites. Site staff will recruit potential participants. Youth will be randomized to receive Healthy Choices, either clinic-based or home-based delivered by the same CHW in both conditions. Outcomes are measured at baseline, 4-, 7-, and 13-months. Data collection for biological measures will be through medical record extraction, and self-reported measures will occur using a brief Web-based CASI (computer-administered self-interviewing) survey on an iPad. All intervention sessions will be audio-recorded for MITI fidelity coding, and investigators will support local supervisors during the active intervention phase. We will conduct qualitative interviews with CHWs, supervisors and organization leaders at the end of the trial to obtain information about barriers and facilitators of implementation. Thus, the proposed trial will allow us to use a Type 1 Effectiveness-implementation hybrid design to pilot a sustainable model of MI implementation in real-world youth care settings towards the goals of 1) examining the effectiveness, cost-effectiveness, and scalability of an efficacious behavioral intervention when delivered by CHWs in real-world adolescent HIV care settings; 2) gathering information about who responds under what contexts; and 3) increasing our understanding of the barriers and facilitators for future implementation. The primary hypothesis is that YLH receiving home-based MET will have greater improvements in alcohol use and viral load than YLH receiving clinic-based MET.

Interventions

The 4-session MET intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the clinic or the home by a CHW (outreach worker, etc) already providing services in the clinic. In sessions 1 and 2 (each behavior will get its own session), CHW will elicit the client's view of the problem using MI techniques, building motivation for change by eliciting and reinforcing change talk. The CHW will deliver feedback and discuss the consideration of a behavior change plan option, and the client sets the change plan goal and consolidates commitment. In the last two sessions, the CHW will review the change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.

Sponsors

Westat
CollaboratorOTHER
City University of New York, School of Public Health
CollaboratorOTHER
University of California, San Diego
CollaboratorOTHER
Medical University of South Carolina
CollaboratorOTHER
University of California, Los Angeles
CollaboratorOTHER
Columbia University
CollaboratorOTHER
University of Alabama at Birmingham
CollaboratorOTHER
Wayne State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
16 Years to 24 Years
Healthy volunteers
No

Inclusion criteria

* HIV-infected * Ability to speak and understand English * Prescribed antiretroviral therapy * Detectable viral load in the last month

Exclusion criteria

* Not fluent in English * History of sever learning disability, mental retardation, major psychiatric disorders (e.g., schizophrenia, bipolar disorder, major depression with psychotic features, etc). * Participation in another adherence intervention trial * On ART due to pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Change in Alcohol Use from Baseline to 9 months post interventionBaseline, 4-, 7-, and 13-monthsWe will use multiple methods of assessing use including calendar-based interview, biomarker, and self-report questionnaire.
Change in Viral Load from Baseline to 9 months post interventionBaseline, 4-, 7-, and 13-monthsViral load will be extracted from medical records, though we have budgeted to collect a percentage of viral loads for youth who drop out of care or transfer to a care setting where records are not available.

Secondary

MeasureTime frameDescription
Change in Medication Adherence from Baseline to 9 months post interventionBaseline, 4-, 7-, and 13-monthsWe will use self-report and interviews that have been successful in our previous trials.
Change in Sexual Risk from Baseline to 9 months post interventionBaseline, 4-, 7-, and 13-monthsWe will use self-report and interviews that have been successful in our previous trials.
Change in Other Substance Use (not alcohol use) from Baseline to 9 months post interventionBaseline, 4-, 7-, and 13-monthsObjective measures are cost prohibitive (e.g., MEMS, hair assays, STI tests, urine screens) for these secondary outcomes; thus we will use self-report and interviews that have been successful in our previous trials.

Other

MeasureTime frameDescription
Barriers and Facilitators of the MI Implementation Process4 months post baselineThe qualitative interview guide (with input from Dr. Norton, consultant) will focus on barriers and facilitators of implementation experienced at the individual, clinic, protocol team, and organizational level. Both positive and potentially negative outcomes will be elicited. Interviews will be conducted at the end of the MET intervention phase to assess sustainability.

Countries

United States

Contacts

Primary ContactSylvie Naar-King, PhD
snaarkin@med.wayne.edu3137454875
Backup ContactPhebe Lam, PhD
plam@med.wayne.edu3135776994

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026